93.242,- på 2 trades i år. Er klar for ny inngang.
En ulempe ved DLBCL er at crossfireeffekten ikke kan utnyttes i samme grad som for FCL…
Disse cellekulturene, er det single layer ?
Grattis med gevinst, Hakon! Lett å se at du er på jakt etter ny, lav inngang…
2 Likes
Ad eierlister, det er vel ganske lett å gjemme seg der… ? Stråselskaper, indexfond og investeringsbanker…
Forresten, er det noen som var på gårsdagens presentasjon som kan dele en stemningsrapport?
Ellers anbefaler jeg Yahoo-Finance-rapporten fra webcasten i forgårs. Ord- for- ord-kringkasting. For de som ikke har hatt anledning til å være til stede på noen av q1-presentasjonene.
(Tidligere link i denne tråden)
Nordic Nanovector Strengthens Management Team with Appointment of Maureen Deehan, PhD, as Head of Corporate Development and Strategy
Oslo, Norway, 1 June 2018
Nordic Nanovector ASA (OSE: NANO) announces that Maureen Deehan, PhD, has been
appointed as Head of Corporate Development and Strategy. Maureen will work
alongside Chief Operating Officer Marco Renoldi on the development and execution
of the Company’s corporate development strategy.Maureen has 25 years’ experience in business development, clinical development
and translational biology. Prior to her appointment, Maureen served for seven
years at Novimmune, a Swiss biotech company developing antibody-based drugs for
the treatment of inflammatory diseases, immune-related disorders and cancer. Her
most recent role there was as Director of Business Development & Alliance
Management, prior to which she held other positions, including Business
Development & Scientific Licensing Lead, Section Head of Translational Research
& Alliance Management, and Head of Pharmacology.Before joining Novimmune, Maureen served as Medical Science Liaison Manager at
Grünenthal UK and as Team Leader of the Department of Molecular Pharmacology at
Organon Laboratories.Maureen has a PhD from the Faculty of Medicine, University of Glasgow and a BSc
in Biochemistry & Pharmacology from the University of Strathclyde.Marco Renoldi, Chief Operating Officer of Nordic Nanovector, commented: “It is
with great pleasure that we welcome Maureen to the team. Her core scientific
expertise in targeted therapies, based on antibodies and related technologies,
combined with a successful track record in business development and deal-making
are an extremely important addition to Nordic Nanovector.”Maureen Deehan added: “I am pleased to be joining Nordic Nanovector at this
important time for the Company as it advances Betalutin® through clinical
development for non-Hodgkin’s lymphoma. I look forward to evaluating relevant
strategic opportunities and working to further build the Company’s business
development network.”For further information, please contact:
IR enquiries Malene Brondberg, VP, Investor Relations and Corporate
CommunicationsTel/Cell: + 44 7561 431 762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: nordicnanovector@citigatedr.co.uk
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
Company aspires to become a leader in the development of targeted therapies for
haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting antibody-radionuclide-conjugate designed to advance the treatment of
non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet
medical need, representing a growing market forecast to be worth nearly USD 20
billion by 2024. Nordic Nanovector intends to retain marketing rights and to
actively participate in the commercialisation of Betalutin® in core markets.Further information can be found at www.nordicnanovector.c
Ekstern link: http://www.newsweb.no/index.jsp?messageId=452749
Nyheten er levert av OBI.
http://www.netfonds.no/quotes/release.php?id=20180601.OBI.20180601S3
3 Likes
Nordic Nanovector Strengthens Management Team with Appointment of Maureen Deehan, PhD, as Head of Corporate Development and Strategy
Oslo, Norway, 1 June 2018
Nordic Nanovector ASA (OSE: NANO) announces that Maureen Deehan, PhD, has been appointed as Head of Corporate Development and Strategy. Maureen will work alongside Chief Operating Officer Marco Renoldi on the development and execution of the Company’s corporate development strategy.
Maureen has 25 years’ experience in business development, clinical development and translational biology. Prior to her appointment, Maureen served for seven years at Novimmune, a Swiss biotech company developing antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. Her most recent role there was as Director of Business Development & Alliance Management, prior to which she held other positions, including Business Development & Scientific Licensing Lead, Section Head of Translational Research & Alliance Management, and Head of Pharmacology.
Before joining Novimmune, Maureen served as Medical Science Liaison Manager at Grünenthal UK and as Team Leader of the Department of Molecular Pharmacology at Organon Laboratories.
Maureen has a PhD from the Faculty of Medicine, University of Glasgow and a BSc in Biochemistry & Pharmacology from the University of Strathclyde.
Marco Renoldi, Chief Operating Officer of Nordic Nanovector, commented: “It is with great pleasure that we welcome Maureen to the team. Her core scientific expertise in targeted therapies, based on antibodies and related technologies, combined with a successful track record in business development and deal-making are an extremely important addition to Nordic Nanovector.”
Maureen Deehan added: “I am pleased to be joining Nordic Nanovector at this important time for the Company as it advances Betalutin® through clinical development for non-Hodgkin’s lymphoma. I look forward to evaluating relevant strategic opportunities and working to further build the Company’s business development network.”
For further information, please contact:
IR enquiries Malene Brondberg, VP, Investor Relations and Corporate Communications
Tel/Cell: + 44 7561 431 762
Email: ir@nordicnanovector.com
International Media Enquiries
Mark Swallow/David Dible/Isabelle Andrews (Citigate Dewe Rogerson)
Tel: +44 207 638 9571
Email: nordicnanovector@citigatedr.co.uk
About Nordic Nanovector
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers.
Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin’s lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.
Further information can be found at www.nordicnanovector.com
Nyheten er levert av Cision.
http://www.netfonds.no/quotes/release.php?id=20180601.Cision.20180531:BIT:2234:0
2 Likes
Noterer meg at de fyller på med lettvektere. De ser nok at selskapet velter.
Men hva skjer med alle meldingene. Fullstendig overload.
8 Likes
Ja det kan se ut som nano sliter med å plukke fra øverste hylle. 
Når korthuset rasa er veien til dagpenger kortere. At folk ikke har ambisjoner asså.
Så skal der uddeles flere PSU’er!
Veldig bra! 
Bare jeg som synes NN virker litt mer på ballen nå? Får minner tilbake til høsten 2016, bortsett fra hallelujastemningen i markedet da…
5 Likes
Har vært på båttur, så beklager sent svar.
Gikk ikke planken!
Du har god teft på aksjer, ser det ut som. Baissing for å få en lav inngang, er en ( forholdsvis) ærlig sak. Men man trenger ikke være ufin.
Nyt ølen og sola! 
Men stump røyken. Vet at det er vanskelig
Ja. Parallelt med at Paradigme kjører for fullt må de bygge organisasjonen så selskapet er klare når de får godkjennelse. Gleder meg til tiden fremover.
“We have a well-designed clinical development plan, aligned with health authority feedback. We have identified a robust market access and reimbursement program. We’ve also – working on optimizing the referral pathways and streamlining the manufacturing and distribution via a centralized logistics partner, rather, to get the Betalutin to the patients.”
- Lisa R.
Godt å høre. Har ikke baisset føler jeg selv. Problemet til nano som flere har nevnt er tillit. Jeg ser de ansetter nå men tviler på at det hjelper i det kortsiktige. Som Irathi så fint påpekte så kommer det lengre tørkeperioder fremover. Og så hardt som nano har blitt mishandlet blir jeg ikke overrasket om vi ser 30 tallet senere i år. Kanskje så lavt som lav 30 også. Nano oppfører seg nå som Funcom har gjort tidligere, pump og dump ved de fleste nyheter. Og en ting jeg har lært. Shorterne vinner alltid. Som Evilfreud har påpekt flere ganger, er man long så legg aksjene i skuffen og ikke tenk mer på de. De som er long vil få betalt i det lange løp, men det blir stygt på veien.
2 Likes
Vet vi ca når denne studien er ferdig ( om alt går smertefritt).
Jepp, de guider til 1H 2020.
Da er det større sjangse for at de allerede prater med partner som kommer inn når resultatene foreligger. DVs at en emmisjon kan bli rimelig tynn og liten.
Du glemmer kombinasjonsstudien med standard of care (Rituxan) pluss studiet i DLBCL hvor de også planlegger pivotal studie for å nå markedet.
Det er mye du ikke har kontroll på som spiller inn på verdiene i NANO 
2 Likes
De lærde strides. Året 2018 er fullt av triggere, 2019 er litt langt frem, men der ser jeg for meg readout ARCHER-1 og DLBCL. Mulig interimstatus på PARADIGME om ny ledelse finner det hensiktsmessig.
Syns påstanden om tørke virker hul.
3 Likes